The future of biological agents in the treatment of rheumatoid arthritis

Rawlings, Charlotte and Choy, Ernest ORCID: https://orcid.org/0000-0003-4459-8609 2014. The future of biological agents in the treatment of rheumatoid arthritis. International Journal of Clinical Rheumatology 9 (5) , pp. 475-486. 10.2217/ijr.14.32

Full text not available from this repository.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease with a currently unknown etiology and multifactorial pathogenesis. This review recaps on the history of development of the main principles of biological disease-modifying agents. Moving into current treatment guidance from Europe and the USA, monotherapy and second-line biological choice is addressed. The reviews explores and summarizes the latest developments and potential impact of anti-cytokine therapy, including TNF, IL-6 and IL-17, anti-lymphocyte therapies, B cell modulators and other B-cell targets, anti-CD3, biosimilars and finally oral agents such as JAK and Syk inhibitors.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > R Medicine (General)
Publisher:	Future Medicine
ISSN:	1758-4272
Last Modified:	28 Oct 2022 10:31
URI:	https://orca.cardiff.ac.uk/id/eprint/78669

Actions (repository staff only)

Edit Item